SNDX - NASDAQ

Syndax Pharmaceuticals, Inc.

SNDX·NASDAQ

$18.34

-2.7%

HealthcareBiotechnology

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.63B

EPS-3.2900

P/E Ratio-5.57

Earnings Date08/03/2026

529.71M

Assets

-27%

3Y+7.0%

5Y+76.0%

10Y+386.0%

465.08M

Total Liabilities

3Y+1461.0%

5Y+860.0%

10Y+1770.0%

64.63M

Total Equity

-78%

3Y-86.0%

5Y-74.0%

10Y-23.0%

Syndax Pharmaceuticals, Inc. Funding & Solvency Profile

SNDX · NASDAQ

Current Assets

Cash & Cash Equivalents134.93M

Net Receivables38.00M

Inventory32.75M

Other Current Assets63.26M

Total Current Assets528 M

Non-Current Assets

Property, Plant & Equipment1.52M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets102.00K

Total Non-Current Assets2 M

Total Assets

529.71M

Financial Health Analysis

Current Ratio

4.40x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

7.20x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

408 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

100% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Syndax Pharmaceuticals, Inc. Balance Sheet

SNDX • NASDAQ

Syndax Pharmaceuticals, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	134.9M	154.1M	295.4M	74.4M	222M	115.2M	24.6M	33.8M	35.2M	23.8M	23.2M	10M	10.1M	537K	3.7M
Short-Term Investments	259.1M	428.8M	282.2M	410M	224.9M	177.8M	35.2M	47.1M	94.8M	81.5M	64.1M	2.2M	4.2M	91K	613K
Cash & Short-Term Investments	394.1M	582.9M	577.6M	484.4M	446.8M	293.1M	59.8M	80.9M	133.2M	105.3M	87.3M	12.2M	14.3M	628K	4.3M
Net Receivables	38M	13.9M	1.2M	4.1M	429K	175K	116K	253K	377K	306K	258K	35K	0.0	0.0	0.0
Accounts Receivables	38M	7.6M	0.0	3.5M	429K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	6.3M	1.2M	583K	0.0	175K	116K	253K	377K	306K	258K	35K	0.0	0.0	0.0
Inventory	32.8M	366K	0.0	0.0	0.0	0.0	0.0	1.1M	-1.4M	2.4M	264K	51K	0.0	0.0	0.0
Prepaids	0.0	7.9M	2M	1.2M	872K	5.2M	380K	289K	1.7M	2.3M	210K	0.0	230K	24K	0.0
Other Current Assets	63.3M	-2M	63K	117K	265K	456K	2.1M	1.8M	1.3M	615K	996K	150K	50K	83K	77K
Total Current Assets	528.1M	603.1M	580.9M	489.8M	448.4M	298.9M	62.3M	83.3M	133.4M	108.5M	88M	12.4M	14.5M	735K	4.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	1.5M	2M	1.5M	1.1M	1.3M	482K	997K	373K	267K	260K	88K	33K	40K	20K	50K
Long-Term Investments	0.0	119.5M	29.8M	5.5M	0.0	0.0	115K	0.0	3.2M	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	102K	217K	680K	922K	0.0	1.3M	82K	219K	231K	243K	1.8M	339K	2.5M	755K	345K
Total Non-Current Assets	1.6M	121.8M	32M	7.5M	1.3M	1.7M	1.2M	592K	3.7M	503K	1.9M	372K	2.5M	775K	395K
Total Assets	529.7M	724.8M	612.9M	497.2M	449.7M	300.6M	63.5M	83.9M	137.2M	109M	89.9M	12.8M	17.1M	1.5M	4.8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	16.6M	11.6M	10M	4.4M	5.7M	3.5M	6.2M	1.4M	2.2M	2.4M	1.5M	354K	1.1M	776K	810K
Accounts Payable	16.6M	11.6M	10M	4.4M	5.7M	3.5M	6.2M	1.4M	2.2M	2.4M	1.5M	354K	1.1M	776K	810K
Accrued Expenses	0.0	0.0	11.2M	17.7M	8.4M	7.5M	2.8M	2.8M	2.4M	1.6M	1.3M	1.6M	1.7M	2.3M	0.0
Short Term Debt	472K	12.1M	0.0	0.0	0.0	2.3M	0.0	0.0	0.0	0.0	0.0	6.4M	0.0	21.3M	10.7M
Capital Lease Obligations (Current)	0.0	480K	1M	439K	362K	316K	478K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	1.5M	1.5M	1.5M	1.6M	1.2M	1.2M	3.4M	0.0	2.4M	0.0
Other Current Liabilities	103.1M	79.3M	35.9M	6.5M	6.2M	3.7M	7.4M	10.3M	9.6M	5.1M	916K	1.9M	0.0	660K	1.9M
Total Current Liabilities	120.1M	103.5M	58.1M	29.1M	20.7M	18.9M	18.4M	16.1M	15.8M	10.4M	4.8M	10.3M	2.7M	25.1M	13.4M
NON-CURRENT LIABILITIES
Long Term Debt	345M	331.6M	0.0	0.0	19.9M	17.8M	0.0	0.0	0.0	0.0	0.0	7.4M	0.0	0.0	8.7M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	11.6M	13.1M	14.7M	16.8M	14.2M	15.4M	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	-1.1M	0.0	0.0	0.0	0.0	1K	5K	136K	310K	288K	2.9M	751K	2.5M	5.7M	1.8M
Total Non-Current Liabilities	345M	333.1M	588K	722K	20.6M	29.6M	13.6M	14.8M	17.1M	14.5M	18.4M	8.2M	2.5M	5.7M	10.4M
Capital Lease Obligations	1.1M	2.1M	1.6M	1.2M	1.1M	417K	897K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4K
Total Liabilities	465.1M	436.7M	58.7M	29.8M	41.3M	48.4M	31.9M	30.9M	32.9M	24.9M	23.2M	18.5M	5.2M	30.8M	23.8M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	137.2M	109M	326.3M	154.1M	147.6M	49M	49M
Common Stock	9K	9K	8K	7K	6K	5K	3K	2K	2K	2K	1K	1K	1K	0.0	0.0
Additional Paid-In Capital	1.6B	1.5B	1.5B	1.2B	952M	820.8M	527.1M	492.5M	470.6M	389.4M	0.0	0.0	0.0	766K	845K
Retained Earnings	-1.5B	-1.2B	-902.4M	-693M	-543.7M	-568.6M	-495.5M	-439.4M	-366.1M	-305.3M	-259.7M	-159.8M	-135.7M	-79.1M	-68.9M
Accumulated Other Comprehensive Income/Loss	452K	163K	218K	-806K	45K	-4K	0.0	-25K	-143K	56K	28K	-185K	-170K	-238K	0.0
Total Stockholders' Equity	64.6M	288.1M	554.2M	467.4M	408.4M	252.2M	31.6M	53M	104.3M	84.1M	66.7M	-5.7M	11.8M	-29.3M	-19.1M
Total Equity	64.6M	288.1M	554.2M	467.4M	408.4M	252.2M	31.6M	53M	104.3M	84.1M	66.7M	-5.7M	11.8M	-29.3M	-19.1M
SUMMARY
Total Liabilities & Equity	529.7M	724.8M	612.9M	497.2M	449.7M	300.6M	63.5M	83.9M	137.2M	109M	89.9M	12.8M	17.1M	1.5M	4.8M
Total Investments	259.1M	548.4M	312M	415.5M	224.9M	177.8M	35.2M	47.1M	98.1M	81.5M	64.1M	2.2M	4.2M	91K	613K
Total Debt	346.5M	345.7M	1.6M	1.2M	21M	20.5M	897K	0.0	0.0	0.0	0.0	13.9M	0.0	21.3M	19.3M
Net Debt	211.6M	191.7M	-293.8M	-73.2M	-201M	-94.7M	-23.7M	-33.8M	-35.2M	-23.8M	-23.2M	3.9M	-10.1M	20.8M	15.6M
Shares Outstanding	86,550,544	86,550,544	86,550,544	86,550,544	86,550,544	86,550,544	86,550,544	86,550,544	86,550,544	86,550,544	86,550,544	86,550,544	86,550,544	86,550,544	86,550,544

SEC Filings

SNDX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	April 30, 2026	April 30, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 30, 2026	April 30, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	April 30, 2026	March 31, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 19, 2025	December 18, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 03, 2025	November 03, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 03, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 24, 2025	October 24, 2025	2025	View Filing

Showing 1 to 10 of 177 filings

Related Guides

Blog Categories

Continue your SNDX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.